Avolynt Announces Initiation of Phase 3 to Evaluate Remogliflozin in Patients with Type 2 Diabetes
A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-center, Active-controlled Study to Evaluate Efficacy and Safety of Remogliflozin Etabonate in Subjects With Type-2 Diabetes Mellitus
Dec 19, 2016
Avolynt Announces Positive Topline Data for Phase 2b BRID Study of SGLT2 Remogliflozin
Avolynt To Present at AASLD’s The Liver Meeting 2016
Avolynt Chief Scientific Officer, William Wilkison, Ph.D. will present the poster titled, “Remogliflozin Etabonate Reduces FIB-4 and NAFLD Fibrosis Scores in Type 2 Diabetic Subjects" on Saturday November 12, 2016 during the session titled “Steatohepatitis: Clinical and Therapeutic.”
Avloynt's successfully completed enrollement of 191 patients in its 12-week phase 2b study of biphasic remogliflozin-etabonate in subjects with type 2 diabetes. Top-line results are expected later in 2016.
Mar 31, 2016
Avolynt, Inc. Completes Acquisition of BHV Pharma
Avolynt successfully completed the acqusition of BHV Pharma.
Mar 09, 2016
Biphasic Patent Issued in European Union
Patent for combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin issued in the Europoean Union.
Mar 09, 2016
Avolynt Submits IND for NASH to FDA
On March 9, 2016, Avolynt submitted an IND to the GI division of the FDA in support of its program in NASH.
Sep 02, 2015
Avolynt Meets with GI Division of FDA for NASH Indication
On September 2nd 2015 Avolynt met with the FDA for a pre-IND meeting to discuss an IND submission for NASH.
Aug 21, 2015
First Patient Randomized in Phase 2b BRID Study
Avolynt successfully randomized first subject into its phase 2b study in type 2 diabetics. The study is a U.S. based twelve-week multi-site, randomized, double blind, placebo controlled study of 191 subjects with type 2 diabetes. Top-line data is expected in 2016.